EMBL and collaborators developed ‘spatialproteomics’, an open-source software that helps researchers analyse complex tissue images and understand how cells are organised within tumours. The tool streamlines a workflow that was previously fragmented, taking users from raw microscopy images through cell segmentation, annotation, and spatial analysis, to biological insight in one unified framework. In studies of B-cell non-Hodgkin lymphoma, the software revealed distinct spatial patterns in tumour and immune cells that helped distinguish between slow-growing and aggressive samples. Spatialproteomics could be useful in studies across many cancers, inflammatory diseases, and in tissues where spatial organisation matters.

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway

Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors

Study: Casdatifan, a new generation HIF-2α blocker, demonstrated durable tumor responses in heavily pretreated patients with advanced kidney cancer. The findings link treatment activity to HIF-2α biology and biomarker changes, supporting precision medicine approaches.

A University of Texas at Dallas researcher has received more than $1 million in grants from the Cancer Prevention & Research Institute of Texas (CPRIT) to develop treatments for solitary fibrous tumor, or SFT. The rare cancer develops when two genes, NAB2 and STAT6, become fused together, resulting in signals that initiate cancer-cell growth. The cause is unknown. While no medications have been developed specifically for SFT, treatment typically involves surgery to remove the tumor and/or radiation.